Telix Pharmaceuticals (TLX) Total Liabilities (2023 - 2025)

Telix Pharmaceuticals (TLX) has reported Total Liabilities for 3 consecutive years, with $748.6 million the latest figure, recorded in Q4 2025.

• Quarterly Total Liabilities rose 11.79% year-over-year to $748.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $748.6 million (up 11.79% YoY) and the FY2025 annual result came in at $748.6 million, up 27.44% from the prior year.
• Total Liabilities rose to $748.6 million in Q4 2025 per TLX's latest filing, from $669.7 million in the prior quarter.
• Over the last five years, Total Liabilities for TLX reached as high as $748.6 million in Q4 2025 and fell as low as $181.5 million in Q4 2023.
• A 3-year average of $533.3 million and a median of $669.7 million in 2024 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2024 — Total Liabilities soared 268.89% — and 2025, when it increased 11.79%.
• Year by year, Total Liabilities stood at $181.5 million in 2023, then surged by 268.89% to $669.7 million in 2024, then gained by 11.79% to $748.6 million in 2025.
• According to Business Quant data, Total Liabilities over the past three periods registered $748.6 million, $669.7 million, and $181.5 million for Q4 2025, Q4 2024, and Q4 2023 respectively.